GLP-1 Products: Every Approved Option Available in 2026 (Full Reference Guide)

The GLP-1 product landscape has never been more crowded.

Key Takeaways

• Two manufacturers dominate: Novo Nordisk and Eli Lilly together account for every major approved GLP-1 product for weight management; AstraZeneca and Sanofi hold older diabetes-only agents.
• Split branding: Same drug, two brand names — Ozempic/Wegovy (semaglutide) and Mounjaro/Zepbound (tirzepatide) — one for diabetes, one for obesity.
• Oral options exist: Rybelsus (T2D), the Wegovy pill (obesity), and Foundayo/orforglipron (obesity) give injection-averse patients real alternatives.
• Weight loss hierarchy: Tirzepatide 15mg > semaglutide 2.4mg > liraglutide 3mg in head-to-head and cross-trial comparisons.
• Compounded versions: Accessible via 503A/503B pharmacies through telehealth prescribers, but the regulatory environment shifted in 2025 — status varies by state and compound.
• pipeline drugs: Retatrutide, CagriSema, and amycretin are in late-stage development and could exceed current agents on weight loss efficacy.

If you're trying to choose between GLP-1 options — or just trying to understand what exists and why your doctor chose a specific one — this is the reference guide that answers both questions. Every approved product is covered here with the practical details: what it's approved for, how it's taken, what the clinical data shows on weight loss, what it costs at list price, and what you need to know about availability. Deeper drug-by-drug comparisons are covered in dedicated articles, but this is the complete map of the current landscape.

How the GLP-1 product market is organized

Two companies built this category.

Novo Nordisk pioneered GLP-1 receptor agonists with liraglutide in 2010 and then semaglutide in 2017, building a portfolio that spans daily and weekly injection, daily oral, T2D and obesity indications. Eli Lilly entered the category more recently with tirzepatide — a dual GLP-1/GIP agonist — and has quickly captured significant market share partly by achieving better weight loss outcomes than pure GLP-1 agents.

Two other companies — AstraZeneca (exenatide) and Sanofi (lixisenatide) — hold older GLP-1 products approved for T2D only that predate the obesity wave. These drugs are still prescribed and still effective for blood sugar management, but they have largely been eclipsed by the newer agents in terms of prescribing volume and weight loss efficacy.

Complete product reference: injectable GLP-1 agents

This is every currently approved injectable GLP-1 product in the United States.

Oral GLP-1 products: what exists and how they differ

Oral GLP-1 is no longer a future concept — it's here now.

Three oral GLP-1 products are available or approved in 2026, each using a different approach to the fundamental problem of getting a GLP-1 drug past the digestive system.

Rybelsus (oral semaglutide, Novo Nordisk, T2D): The same semaglutide molecule used in Ozempic and Wegovy, formulated with SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), an absorption enhancer that allows absorption through the stomach wall before digestive enzymes reach the drug. Approved for T2D, not weight management. Requires fasting dosing: taken on an empty stomach with no more than 4oz of water, with no food or other medications for 30 minutes after. Despite the complex dosing requirements, it provides a meaningful alternative to injection for T2D patients. Available at 3mg, 7mg, and 14mg doses. Weight loss data in T2D is similar to injectable semaglutide at equivalent doses. List price approximately $936/month.

Wegovy pill (oral semaglutide 50mg, Novo Nordisk, obesity): A higher-dose oral semaglutide formulation approved specifically for weight management. At 50mg, the oral dose is much higher than Rybelsus because of lower bioavailability through the oral route — the drug absorbed through the stomach is a fraction of what is injected. Phase 3 data (OASIS 1) showed approximately 15.1% body weight reduction over 68 weeks, comparable to injectable Wegovy. Also uses the SNAC delivery system and requires the same fasting dosing protocol as Rybelsus. This is a significant development for patients who prefer not to inject. List price pending — expected to be similar to injectable Wegovy.

Foundayo / Orforglipron (Eli Lilly, obesity): A non-peptide GLP-1 receptor agonist — meaning it is a small molecule, not a peptide, so it does not get broken down by digestive enzymes. This allows it to be taken as a standard daily pill with no fasting requirement and no special absorption mechanism. Phase 3 trials showed approximately 14.7% body weight reduction over 36 weeks in patients with obesity. Because it is a small molecule, it can also be manufactured at far lower cost than peptide drugs — an important factor for long-term global access. Daily dosing at a single dose level (dose established in Phase 3 as approximately 45mg). List price not yet established at time of writing.

Compounded GLP-1 options: the 2025 regulatory shift

Compounded semaglutide was a major access story — and the rules changed.

When semaglutide was listed on the FDA Drug Shortage list (2022–2024), federal compounding law permitted 503A (patient-specific) and 503B (outsourcing facility) pharmacies to compound semaglutide as an alternative to branded products. This opened a pathway for telehealth platforms to prescribe compounded semaglutide at substantially lower prices than branded Wegovy or Ozempic — often $100–$300 per month versus $1,000+.

In 2025, the FDA removed semaglutide from the shortage list, which triggered a change in the legal status of compounded semaglutide. Under federal law, pharmacies generally cannot compound drugs that are not on the shortage list unless specific patient-specific criteria apply. The FDA took enforcement action against some 503B facilities compounding semaglutide post-shortage designation. The situation for 503A patient-specific compounding is more nuanced and varies by state.

Compounded tirzepatide had a different regulatory timeline — it entered and remained on the shortage list longer, and compounded versions remained more widely available through mid-2025. The current status in 2026 should be confirmed with a licensed prescriber who practices in your state.

If you are currently receiving compounded semaglutide through a telehealth platform, the most important step is confirming with your prescriber that the pharmacy supplying your medication is operating in compliance with current FDA guidance. Compliance status varies by facility and state. Your prescriber should be able to confirm this — if they cannot, that is a reason to ask more questions.

What to know about availability and shortage history

Supply has improved but the history matters for planning.

Ozempic and Wegovy both appeared on the FDA Drug Shortage list beginning in 2022 due to manufacturing constraints and demand surge. This affected T2D patients most severely — those who depended on Ozempic for glycemic control found themselves unable to fill prescriptions. The shortage also drove the compounded semaglutide market.

By 2025, Novo Nordisk significantly expanded manufacturing capacity. Ozempic and Wegovy are generally in stock at major pharmacies in 2026, though specific doses may occasionally be backordered at individual locations. Checking availability with multiple pharmacies — including mail-order pharmacy options — before transferring a prescription is still a reasonable practice given the shortage history.

Mounjaro and Zepbound (tirzepatide) also appeared on shortage lists as demand surged post-launch. Supply has normalized for most doses through 2025–2026. Older agents (Trulicity, Byetta, Victoza) have not experienced significant shortage issues and remain reliably available where still prescribed.

What's coming: the pipeline

The drugs in development may outperform everything currently available.

Retatrutide (Eli Lilly): A triple agonist — GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 data showed approximately 24% body weight reduction at 48 weeks, exceeding tirzepatide's Phase 3 results. Phase 3 trials are underway. If approved, this would represent the highest-efficacy weight loss drug yet seen in clinical trials.

CagriSema (Novo Nordisk): A combination of cagrilintide (an amylin analogue) and semaglutide. Phase 3 trial data from REDEFINE 1 showed approximately 22.7% weight loss at 68 weeks — competitive with tirzepatide. Pending regulatory review for obesity indication.

Amycretin (Novo Nordisk): A unimolecular combination of GLP-1 and amylin receptor agonism in a single molecule. Early-phase data showed 22% weight loss in 12 weeks in a small Phase 1/2 cohort — a notably large effect for a short time window. Phase 3 data not yet available. Oral formulation also in development.

These pipeline agents represent the next generation rather than imminent options. If you are starting GLP-1 treatment now, current approved options — particularly tirzepatide — are both effective and backed by large-scale safety data that pipeline drugs have not yet accumulated.

How to choose between the products

The choice depends on four practical factors.

First, your diagnosis. If you have T2D, your prescriber will weigh both blood sugar control and weight loss goals — and may select a drug approved for T2D over one approved only for obesity, or vice versa depending on insurance coverage. Second, injection vs. oral preference. If you will reliably take a daily pill but would avoid a weekly injection, an oral agent changes the calculus even if its weight loss data is marginally lower. Third, cost and coverage. What your insurance covers, and what savings programs are available, may determine which drug is actually accessible. Fourth, how much weight loss you're targeting. If a 20%+ weight loss is the clinical goal, tirzepatide has the strongest data; if 15% is the goal, semaglutide achieves it with a longer track record.

None of these decisions require you to know the entire product landscape — but having the landscape mapped means you can ask better questions when you sit down with your prescriber.

Frequently Asked Questions

Is Zepbound cheaper than Wegovy?
At list price, yes — Zepbound lists at approximately $550/month versus Wegovy's approximately $1,349/month. This gap reflects Eli Lilly's deliberate pricing strategy for Zepbound. However, with manufacturer savings cards, both drugs can be brought to approximately $25/month for eligible commercially insured patients. The insurance coverage and savings card situation matters as much as list price in most cases.

Can I switch from semaglutide to tirzepatide?
Switching is clinically feasible and happens with some frequency when patients plateau on semaglutide or when their insurer's coverage changes. The switch protocol is not standardized — some providers restart at the lowest tirzepatide dose; others start at a mid-range dose accounting for previous GLP-1 exposure. This is a conversation for your prescriber, who will guide the transition based on your specific situation.

Are exenatide or lixisenatide ever still prescribed for weight loss?
Rarely, in 2026. Exenatide (Byetta/Bydureon) and lixisenatide (Adlyxin) produce 1–3% weight loss — far less than semaglutide or tirzepatide. They are occasionally still prescribed for T2D when other agents are contraindicated or unavailable, but they are not competitive for weight management given what newer agents achieve. Any patient on these older agents specifically for weight management would likely do better on a newer agent.

When will generics be available?
GLP-1 drugs are under patent protection that extends well into the 2030s for the major products. Semaglutide's core patents do not expire until 2032–2033. Generic (biosimilar) versions require both patent expiration and a complex biologics approval pathway. Lower-cost small-molecule alternatives like orforglipron may provide some cost relief before generic semaglutide arrives, but brand-name pricing pressure will remain a feature of this market for years.

Do pipeline drugs mean I should wait before starting treatment?
No. Current agents — particularly tirzepatide at 15mg — are producing 20%+ average weight loss in clinical trials. The health benefits of treating obesity do not pause while better drugs develop. Starting treatment with the best available current option and reassessing when new agents are approved is the clinically sound approach. Waiting for a pipeline drug to reach approval is typically measured in years, not months, and carries the continued health cost of untreated obesity in the interim.

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any medication.